INZY — Inozyme Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
Annual cashflow statement for Inozyme Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -56.4 | -56.6 | -67.1 | -71.2 | -102 |
| Depreciation | |||||
| Non-Cash Items | 20.3 | 7.71 | 6.54 | 2.74 | 4.66 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.111 | 0.085 | 2.01 | -3.08 | 4.71 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36 | -48.2 | -57.8 | -70.7 | -91.9 |
| Capital Expenditures | -0.568 | -0.397 | -0.41 | -0.298 | -0.062 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -117 | 43.2 | -4.99 | -53.3 | 67.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -117 | 42.8 | -5.4 | -53.6 | 67 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 150 | 0.609 | 72.8 | 126 | 11.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.34 | -4.72 | 9.6 | 1.63 | -13.5 |